Evidence map›Paper›PMID 38001731›Full record

ArticleCancers2023

Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features?

Riccardo Laudicella, Matteo Bauckneht, Alexander Maurer, Jakob Heimer, Antonio G Gennari, Tania Di Raimondo, Gaetano Paone, Marco Cuzzocrea, Michael Messerli, Daniel Eberli and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. [European journal of nuclear medicine and molecular imaging · 2025
    Article
  2. Composite Prediction Score to Interpret Bone Focal Uptake in Hormone-Sensitive Prostate Cancer Patients Imaged with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Riccardo LaudicellaDepartment of Nuclear Medicine, Cantonal Hospital Baden, 5404 Baden, Switzerland.ORCID 0000-0002-2842-0301
Matteo BaucknehtNuclear Medicine, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.ORCID 0000-0002-1937-9116
Alexander MaurerDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, 8006 Zurich, Switzerland.ORCID 0000-0002-6964-802X
Jakob HeimerDepartment of Mathematics, Seminar for Statistics, ETH Zurich, 8092 Zurich, Switzerland.
Antonio G GennariDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, 8006 Zurich, Switzerland.ORCID 0000-0003-2224-0083
Tania Di RaimondoDepartment of Health Sciences (DISSAL), University of Genova, 16126 Genova, Italy.
Gaetano PaoneClinic for Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.
Marco CuzzocreaClinic for Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland.ORCID 0000-0002-8214-562X
Michael MesserliDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, 8006 Zurich, Switzerland.
Daniel EberliDepartment of Urology, University Hospital of Zurich, 8006 Zurich, Switzerland.ORCID 0000-0001-8866-8010
Irene A BurgerDepartment of Nuclear Medicine, Cantonal Hospital Baden, 5404 Baden, Switzerland.
University of Zurich · CHEnte Ospedaliero Cantonale · CHETH Zurich · CHOspedale Policlinico San Martino · ITUniversity Hospital of Zurich · CHUniversity of Genoa · ITUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe increasing use of PSMA-PET/CT for restaging prostate cancer (PCa) leads to a patient shift from a non-metastatic situation based on conventional imaging (CI) to a metastatic situation. Since established therapeutic pathways have been designed according to CI, it is unclear how this should be translated to the PSMA-PET/CT results. This study aimed to investigate whether PSMA-PET/CT and clinical parameters could predict the visibility of PSMA-positive lesions on a bone scan (BS).

methodsIn four different centers, all PCa patients with BS and PSMA-PET/CT within 6 months without any change in therapy or significant disease progression were retrospectively selected. Up to 10 non-confluent clear bone metastases were selected per PSMA-PET/CT and SUV

resultsA total of 43 patients were identified with 222 bone lesions on PSMA-PET/CT. A total of 129 (58.1%) lesions were visible on the BS. In the univariate analysis, all PSMA-PET/CT parameters were significantly associated with the visibility on the BS (

conclusionsThese preliminary results indicate that there might be a way to predict the BS results based on PSMA-PET/CT, potentially improving the comparability between both examinations and supporting decisions for therapy selection.

Indexed as

generalized linear mixed modelpredictionprostate cancerPSMA PETstaging

Identifiers

PMID38001731
PMCPMC10670186
OpenAlexW4388832878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.